Clinical Trial News and Research

RSS

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Agents designed to attack blood vessels that feed a growing tumor are effective against tumor growth in laboratory experiments. However, results of early clinical trials with these inhibitors have not yet exhibited the same success observed in animal models.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Detrol LA significantly reduces symptoms of overactive bladder

Pfizer today announced results of a comprehensive six-year review of efficacy and safety data for Detrol LA (tolterodine tartrate extended release capsules) indicating that Detrol LA significantly reduces symptoms of overactive bladder (OAB) with a low occurrence of side effects, and should be considered first-line therapy.

13 Dec 2004

Start today of human tests for a preventive vaccine against the respiratory disease SARS

Powerful research tools that speed up vaccine development have led to the start today of human tests for a preventive vaccine against the respiratory disease SARS. The disease killed hundreds of people around the world before it was brought under control in 2003 with aggressive conventional public health measures.

13 Dec 2004

Lupus drug may also be useful in treating psoriasis

A new drug candidate previously shown to reduce harmful side effects of the autoimmune disease lupus also may be useful in treating psoriasis.

13 Dec 2004

Using precise, radioactively labeled genetic probes, researchers study cancer gene activity from outside the body

Using precise, radioactively labeled genetic probes, researchers at Jefferson Medical College have seen cancer gene activity from outside the body in laboratory mice. The probes, which work by attaching to genetic codes copied from an active cancer gene, may someday aid physicians and scientists in cancer detection and in determining the appropriate treatment for a cancer.

13 Dec 2004

Short course of radiation therapy following lumpectomy

Fox Chase Cancer Center researchers have presented preliminary results of a clinical trial in which women received a two-week shorter course of radiation therapy than the current standard following a lumpectomy.

13 Dec 2004

FDA approves Topigen's investigational New Drug Application for new inhalation drug to treat asthma

Phase 1 clinical trial can be initiated for ASM8, a new inhalation drug that is designed to treat asthma through a unique approach by attacking multiple mediators of the inflammatory mechanism rather than the single mediator approach of current therapies.

8 Dec 2004

Lilly launches publicly available clinical trial registry

Eli Lilly and Company today will announce the launch of its publicly available clinical trial registry, www.lillytrials.com, which will post the results from all Phase I through Phase IV clinical trials of Lilly's marketed products.

8 Dec 2004

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.

7 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Review findings released on the safety of antidepressants (SSRI's)

The Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice to patients and doctors about the group of antidepressants known as SSRI's, today.

6 Dec 2004

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Heart Hospital begins experimental cell therapy

Physicians at the Heart Hospital became the first team in the UK to treat a patient with an experimental new therapy designed to repair damage to cardiac muscle resulting from a heart attack. If successful, this treatment would give doctors the ability to improve the hearts of people with heart failure, rather than just treating the symptoms.

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Clinical Trial News and Research

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Celebrex suspension

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

Detrol LA significantly reduces symptoms of overactive bladder

Start today of human tests for a preventive vaccine against the respiratory disease SARS

Lupus drug may also be useful in treating psoriasis

Using precise, radioactively labeled genetic probes, researchers study cancer gene activity from outside the body

Short course of radiation therapy following lumpectomy

FDA approves Topigen's investigational New Drug Application for new inhalation drug to treat asthma

Lilly launches publicly available clinical trial registry

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

New advances in sickle cell disease

Review findings released on the safety of antidepressants (SSRI's)

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Heart Hospital begins experimental cell therapy

New drug can successfully treat patients who have become resistant to Gleevec

Researchers step closer to cure for common childhood cancer

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Single dose phase I data on CG53135 for the prevention of oral mucositis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News